Therapeutic targets for hepatitis D virus infection
Hepatitis D is an inflammatory disease of the liver caused by infection with the hepatitis D virus (HDV). It is the most severe form of viral hepatitis affecting humans. It infects between 15 and 20 million people worldwide, all of whom are also infected with hepatitis B virus (HBV). HDV infection can cause both acute and chronic hepatitis; the outcome is determined by the host response to hepatitis B. In general, HBV-HDV coinfection results in acute, but rarely chronic, disease. The coinfection pattern ranges from asymptomatic or mild disease to fulminant hepatitis. In contrast HDV superinfection in HBV carriers leads to more a severe, chronic form of disease manifesting as fulminant hepatic failure, rapidly developing cirrhosis and hepatic decompensation. Because HDV absolutely requires the envelope proteins of HBV to be infectious, the most effective method of preventing hepatitis D at this time is vaccination against HBV. Peginterferon alfa has been used in the treatment of hepatitis D for more than 20 years and is the most effective treatment option, although it eradicates the disease in only a minority of patients. Other putative treatments for HDV infection include prenylation inhibitors, entry inhibitors and HBsAg release inhibitors. This article presents those drug targets that are currently under active investigation for the treatment of HDV infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:043 |
|---|---|
| Enthalten in: |
Drugs of the future - 043(2018), 3, Seite 0189 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sorbera,US!aL. [VerfasserIn] |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC2000500056 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2000500056 | ||
| 003 | DE-627 | ||
| 005 | 20230516073303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180809s2018 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a fidpha__2018-08-09.pp |
| 035 | |a (DE-627)OLC2000500056 | ||
| 035 | |a (DE-599)GBVOLC2000500056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Sorbera,US!aL. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic targets for hepatitis D virus infection |
| 264 | 1 | |c 2018 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hepatitis D is an inflammatory disease of the liver caused by infection with the hepatitis D virus (HDV). It is the most severe form of viral hepatitis affecting humans. It infects between 15 and 20 million people worldwide, all of whom are also infected with hepatitis B virus (HBV). HDV infection can cause both acute and chronic hepatitis; the outcome is determined by the host response to hepatitis B. In general, HBV-HDV coinfection results in acute, but rarely chronic, disease. The coinfection pattern ranges from asymptomatic or mild disease to fulminant hepatitis. In contrast HDV superinfection in HBV carriers leads to more a severe, chronic form of disease manifesting as fulminant hepatic failure, rapidly developing cirrhosis and hepatic decompensation. Because HDV absolutely requires the envelope proteins of HBV to be infectious, the most effective method of preventing hepatitis D at this time is vaccination against HBV. Peginterferon alfa has been used in the treatment of hepatitis D for more than 20 years and is the most effective treatment option, although it eradicates the disease in only a minority of patients. Other putative treatments for HDV infection include prenylation inhibitors, entry inhibitors and HBsAg release inhibitors. This article presents those drug targets that are currently under active investigation for the treatment of HDV infection. | ||
| 700 | 1 | |a Dulsat,US!aC. |e verfasserin |4 aut | |
| 700 | 1 | |a Graul,US!aA.I. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of the future |d Barcelona : Prous Science - Thomson Reuters, 1976 |g 043(2018), 3, Seite 0189 |w (DE-627)13048489X |w (DE-600)752959-4 |w (DE-576)016071395 |x 0377-8282 |7 nnns |
| 773 | 1 | 8 | |g volume:043 |g year:2018 |g number:3 |g pages:0189 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4125 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 043 |j 2018 |e 3 |h 0189 | ||